Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of encorafenib + binimetinib in BRAF V600E-mutant non-small cell lung cancer
2019-000417-37Phase 2Active
- Sponsor
- Array BioPharma
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and binimetinib in non-small cell lung cancer (NSCLC), sponsored by Array BioPharma. Primary endpoint: Objective response rate. Started Jun 2019; status: active.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-000417-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000417-37.